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Abstract
Background: Cutaneous mast cell tumours are one of the most common neoplasms in dogs and
show a highly variable biologic behaviour. Several prognosis tools have been proposed for canine
mast cell tumours, including histological grading and cell proliferation markers. CD117 is a receptor
tyrosine kinase thought to play a key role in human and canine mast cell neoplasms. Normal
(membrane-associated) and aberrant (cytoplasmic, focal or diffuse) CD117 immunoexpression
patterns have been identified in canine mast cell tumours. Cytoplasmic CD117 expression has been
found to correlate with higher histological grade and with a worsened post-surgical prognosis. This
study addresses the role of CD117 in canine mast cell tumours by studying the correlations
between CD117 immunoexpression patterns, two proliferation markers (Ki67 and AgNORs)
histological grade, and several other pathological variables.
Results: Highly significant (p < 0,001) correlations were found between CD117 immunostaining
patterns and histological grade, cell proliferation markers (Ki67, AgNORs) and tumoral necrosis.
Highly significant (p < 0,001) correlations were also established between the two cellular
proliferation markers and histological grade, tumour necrosis and epidermal ulceration. A
significant correlation (p = 0.035) was observed between CD117 expression patterns and
epidermal ulceration. No differences were observed between focal and diffuse cytoplasmic CD117
staining patterns concerning any of the variables studied.
Conclusion: These findings highlight the key role of CD117 in the biopathology of canine MCTs
and confirm the relationship between aberrant CD117 expression and increased cell proliferation
and higher histological grade. Further studies are needed to unravel the cellular mechanisms
underlying focal and diffuse cytoplasmic CD117 staining patterns, and their respective
biopathologic relevance.
Background
While remaining infrequent in human beings, cutaneous
mast cell tumours (MCTs) are one of the most common
tumours in dogs, accounting for about 6% of all tumours
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MCTs have attracted increasing attention in recent years,
as spontaneous models for studying mast cell neoplastic
disorders and developing new targeted chemotherapeutic
drugs [2-4]. The biological behaviour of canine MCTs can
vary widely and is often difficult to predict [1]. Histologi-
cal grading [5] is widely used for prognosis analysis [6],
but its adequacy remains debatable [7]. According to the
internationally adopted system, MCTs are usually graded
as well-differentiated (grade I), moderately differentiated
(grade II) or poorly differentiated (grade III) tumours.
Other prognostic factors have recently been proposed,
most notably proliferation markers such as Ki67 (MIB-1)
nuclear antigen labelling index and AgNORs mean counts
[8-11]. Recent studies have demonstrated both normal
(membrane associated) and abnormal (cytoplasmic, focal
or diffuse) CD117 immunoexpression patterns in canine
MCTs [12-14]. CD117 cytoplasmic expression patterns
have been shown to correlate with reduced post-surgical
survival [15]. Together with it's ligand (stem cell factor –
SCF), also known as Steel factor or KIT ligand, CD117
(also referred as KIT or c-KIT) is a critical transmembrane
receptor tyrosine kynase for a number of cell types, includ-
ing some hematopoietic stem cells, mast cells, melano-
cytes, and germ cells. Binding of SCF by CD117 leads to
receptor dimerization and activation of its tyrosine kynase
activity [16]. A number of signal transduction pathways,
such as the PI3-kinase and the RAS/Erk pathways have
been implicated in mediating CD117 functions in mast
cells, including cellular proliferation and differentiation,
resistance to apoptosis, mobility and chemotaxis, adhe-
sion to fibronectin and enhancement of serotonin and
histamine release [17-19]. CD117 is encoded by the
proto-oncogene c-kit [16]. Point mutations of this gene
have been associated with human mastocytosis [20,21]
and other malignancies [22-26] while c-kit exon 11 dele-
tions and duplications have been identified in canine
MCTs [27-30]. This work aims to study the role of CD117
in canine MCTs by analysing the correlations between
CD117 immunoexpression patterns, two proliferation
markers (Ki67 and AgNORs), histological grading, and
several pathological variables.
Results
49 (47.6%) tumours presented a membrane-associated
CD117 staining pattern (Figure 1), while 46 (44.7%)
showed focal cytoplasmic staining (Figure 2) and 8
(7.8%) diffuse cytoplasmic staining (Figure 3). Ki67 label-
ling index ranged from 3.3 to 46.6, while mean nuclear
AgNORs counts ranged from 1.1 to 4.2. Histologically, 35
(34.0%) tumours were grade I, 45 tumours (43.7%) were
grade II and 22 tumours (22.3%) were grade III. Highly
significant statistical correlations (p < 0,001) were found
between CD117 staining patterns and histological grade,
presence of necrosis and mitotic index (Table 1). How-
ever, no differences were observed between focal and dif-
fuse staining patterns, concerning any of the variables
studied. Highly significant statistical correlations (p <
0,001) were also established between Ki67 labelling index
and CD117 staining patterns, histological grade, mitotic
index and presence of necrosis and ulceration (Table 2) as
well as between these variables and AgNORs counts
(Table 3). Figure 4 shows a linear correlation between
Ki67 labelling index and mean AgNOR counts (R Spear-
man correlation coefficient 0.639) and the distribution of
Focal cytoplasmic (Golgi-like) CD117 immnostainingigure 2
Focal cytoplasmic (Golgi-like) CD117 immnostaining. 
Canine cutaneous MCT showing focal cytoplasmic immunos-
taining for anti-CD117 antibodies. ABC 400×. Bar = 20 µm.
Membrane-associated CD117 immunostainingFigure 1
Membrane-associated CD117 immunostaining. 
Canine cutaneous MCT showing membrane-associated 
immunostaining for anti-CD117 antibodies. ABC 400×. Bar = 
20 µm.Page 2 of 7
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cytoplasmic) according to these proliferation markers.
AgNORs mean counts were significantly higher in MCTs
showing cytoplasmic CD117 expression (p < 0,001). A
significant correlation was found between CD117 cyto-
plasmic pattern and epidermal ulceration (p = 0.035). No
significant statistical correlation was established between
any pathologic variables and the sex, age or breed of the
animals, nor with the number (single/multiple) or loca-
tion (head and neck, trunk, limbs, perineal) of the lesions.
Discussion
The predominance of the Boxer breed among the animals
studied reflects a well-known breed predisposition for
canine MCTs. However, no significant correlations were
found between the breed of the animals and any other of
the variables now studied, and the significance of breed
regarding the biopathology of MCTs remains unclear. The
linear correlation observed between Ki67 labelling index
and mean AgNOR counts validates the results of each
technique and allows for confirmation of differences in
cellular proliferation by two independent methods. The
Ki67 labelling index increases in a step-wise way from his-
tological grade I to III, but there is considerable overlap-
ping of both AgNORs and Ki67 values between
histological grades. Results have highlighted a strong cor-
relation between cytoplasmic (altered) CD117 immu-
noexpression and increased cell proliferation and higher
histological grade (itself partly based on mitotic index)
when compared with the normal, membrane-associated
expression pattern. Two distinct patterns for CD117 cyto-
plasmic staining (a focal, paranuclear, sometimes referred
to as Golgi-like pattern and a diffuse pattern) have been
described [12-15]. In this study, no significant differences
were found between focal and diffuse cytoplasmic CD117
staining, concerning any of the variables studied. This sug-
gests that focal and diffuse cytoplasmic staining may
reflect similar cellular changes and, possibly, a progressive
cytoplasmic accumulation of CD117. Additional studies
are needed to elucidate the biopathologic relevance of
these expression patterns as well as the corresponding
underlying cellular mechanisms. C-kit mutations have
been shown to induce ligand-independent (constitutive)
CD117 phosphorylation and activation in human neo-
plasms, both by impairing the regulatory functions of the
juxtamembrane domain and by directly targeting the
kinase domain [31]. Such mutations are likely to be the
cause of increased cell proliferation in MCTs showing
cytoplasmic CD117 expression. It is interesting to specu-
late that mutations causing constitutive CD117 phospho-
rylation may also collide with the intracellular traffic of
CD117 and cause the molecule to accumulate in cellular
organelles, such as the Golgi apparatus or the endoplas-
mic reticulum. C-kit mutations have been shown to corre-
late with altered CD117 expression, though mutations
Diffuse cytoplasmic CD117 immnostainingFig r  3
Diffuse cytoplasmic CD117 immnostaining. Canine 
cutaneous MCT showing diffuse cytoplasmic immunostaining 
for anti-CD117 antibodies. ABC 400×. Bar = 20 µm.
Table 1: CD117 immunoexpression in canine MCTs (membrane-
associated versus cytoplasmic staining): correlations with 
multiple pathologic variables
Pathologic 
variables
CD117 expression pattern P value
membrane-
associated
cytoplasmic
Histological 
grade
I 24 (49.0%) 11 (20.4%) p < 0,001
II 22 (44.0%) 23 (42.6%)
III 3 (6.1%) 20 (37.0%)
Necrosis
No 44 (89.8%) 29 (53.7%) p < 0,001
Yes 5 (10.2%) 25 (46.3%)
Growth 
pattern
well 
circumscribed
7 (14.3%) 5 (9.3%) P = 0,427
invasive 42 (85.7%) 49 (90.7%) (NS)
Ulceration
No 40 (81.6%) 34 (63.0%) P = 0,035
yes 9 (18.4%) 20 (37.0%)
Mitosis (per 
high power 
field)
0 37 (75.5%) 22 (40.7%)
1 11 (22.4%) 8 (14.8%) p < 0,001
2 1 (2.0%) 10 (18.5%)
≥ 3 0 (0.0%) 14 (25.9%)
NS – non-significantPage 3 of 7
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Table 2: Ki67 labelling index in canine MCTs: correlations with multiple pathologic variables
Pathologic variables Ki67 labelling index (p value)
median min. max. IR
Histological grade
I 7.1 3.3 14.9 3.2
II 13.3 3,9 32.7 12.9 p < 0,001
III 32.2 15.4 46.6 8.5
Necrosis
No 9.7 3.3 38.6 10.2 p < 0,001
Yes 27.7 6.2 46.6 20.6
Growth pattern
well circumscribed 8.2 4.1 46.6 13.8 P = 0,158
Invasive 12.7 3.3 45.1 17.4 NS
Ulceration
No 9.8 3.3 46.6 10.8 p < 0,001
Yes 29.4 4.5 45.1 19.4
Mitoses (per high 
power field)
0 8.6 3.3 29.7 4.7
1 16.0 9.3 30.8 11.3 p < 0,001
2 29.2 15.4 45.1 15.1
≥ 3 33.7 30.9 46.6 7.5
CD117 staining 
pattern
membrane-associated 9.2 3.3 29.7 6.0
cytoplasmic focal 23.9 4.1 46.6 21.7 p < 0,001
cytoplasmic diffuse 19.1 5.8 45.1 21.6
IR – interquartile range, NS – non-significant.
Table 3: AgNORs mean counts in canine MCTs: correlations with multiple pathologic variables
Pathological variables AgNORs mean counts (p value)
Median min. max. IR
Histological grade
I 1.3 1.1 2.3 0.4
II 1.5 1.1 2.9 0.5 p < 0.001
III 2.4 1.2 4.2 1.6
Necrosis
No 1.4 1.1 3.8 0.5 p < 0.001
yes 1.9 1.2 4.2 1.3
Growth pattern
well circumscribed 1.3 1.2 4.2 0.6 P = 0.245
invasive 1.6 1.1 3.8 0.7 (NS)
Ulceration
no 1.4 1.1 4.2 0.5 p < 0.001
yes 1.8 1,2 3.8 1.3
Mitoses (per high 
power field)
0 1.4 1.1 2.7 0.4
1 1.6 1.2 2.9 0.4 p < 0.001
2 2.3 1.3 3.5 1.3
≥ 3 2.6 1.8 4.2 1.4
CD117 staining
membrane-associated 1.3 1.1 2.3 0.4
cytoplasmic focal 1.9 1.1 4.2 1.2 p < 0,001
cytoplasmic diffuse 1.6 1.2 3.4 1.3
IR – interquartile range, NS – non-significant.
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sion [32]. By elucidating the precise cellular location of
cytoplasmic CD117 accumulations, especially in those
lesions presenting a "Golgi-like" pattern, a deeper insight
into the role of this molecule in tumorigenesis may per-
haps be gained. Results suggest that translocation of
CD117 into the cytoplasm correlates with activation of
CD117-mediated cell proliferation. Although increased
cell proliferation in itself is insufficient for neoplastic
transformation, it may contribute to the malignant phe-
notype by increasing the risk of spontaneous mutations.
Some human neoplasms have been demonstrated to
present an autocrine loop in which neoplastic cells
express both SCF and CD117 [33], thus securing perma-
nent growth stimulation. This hypothesis has not been
investigated in the case of canine MCTs and should be
addressed in future studies. The correlation observed
between tumoral necrosis and cytoplasmic CD117 expres-
sion (Table 1) may reflect increased cellular proliferation,
insufficiently accompanied by angiogenesis, as suggested
by the correlation observed between necrosis and higher
Ki67 labelling index (Table 2). On the other hand, the cor-
relation between the CD117 cytoplasmic pattern and epi-
dermal ulceration may be due to a CD117-mediated
enhancement of histamine and serotonine release and
consequent pruritus and self-induced trauma. CD117
might also be thought to play a role in tumoral progres-
sion, as suggested by the correlation of cytoplasmic
CD117 staining and higher histological grade, by facilitat-
ing neoplastic cell mobility and binding of fibronectin.
The tumoral growth pattern (well circumscribed versus
invasive) and the clinical variables studied (race, sex, age,
tumour number and location) have shown no correla-
tions with any of the pathological variables studied. The
available survival data doesn't allow for conclusions as to
which of the factors now studied is more suitable for prog-
nostic analysis.
Conclusion
Cytoplasmic (altered) expression of CD117 correlates
with increased cellular proliferation, as assessed by both
Ki67 labelling index and by AgNORs mean counts. This is
in accordance with the known functions of CD117 as a
growth factor receptor and is probably associated with a c-
kit mutation. Moreover, cytoplasmic CD117 expression
also correlates with increased histological grade, tumour
necrosis and epidermal ulceration. No differences were
observed between focal and diffuse cytoplasmic staining
patterns, suggesting that these represent similar cellular
changes, or perhaps a progressive process of cytoplasmic
CD117 accumulation. Our future aims are to look for pos-
sible mutations in the c-kit gene in canine MCCs.
Methods
Samples collection and processing
103 MCTs surgically removed from 67 dogs, between
2000 and 2006, were sent for examination at the ICBAS-
UP Veterinary Pathology laboratory. The animals com-
prised 30 males and 37 females, with ages ranging
between 2 and 20 years and a mean age of 7.3 years. 33
(49.25%) animals were of the Boxer breed, 18 (26.87%)
of mixed breed and 16 (23.88%) of other breeds (with 3
or less animals of each breed). All nodules were consid-
ered as primary MCTs, even when occurring in a multiple
pattern. Samples were fixed in 10% buffered formallin
and paraffin-embedded. Thin serial sections were
obtained for each sample and used for routine haematox-
ylin-eosin (H&E) staining, AgNOR staining and immuno-
histochemical detection of CD117 and Ki67. 3 µm-thick
sections were used for all techniques except AgNORs (4
µm).
Histological evaluation
Histological grading was performed on H&E-stained
slides, following Patnaik's system [5], by two independent
pathologists (RMGC and FG). When grading differed,
decision was taken by consensus. The number of mitotic
figures per high power field and other pathologic changes,
such as tumoral necrosis and epidermal ulceration were
also noted.
AgNORs staining
AgNOR staining was performed as previously described
[34]. The staining solution was freshly prepared for each
experiment, from a 2% gelatin solution (Merck) and 50%
Correlations between Ki67 labelling index, AgNORs mean counts and CD117 stain ng p tter sFigure 4
Correlations between Ki67 labelling index, AgNORs mean 
counts and CD117 staining patterns.Page 5 of 7
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in the staining solution under conditions of reduced light
for 45 minutes and washed in deionised water. Silver
deposits were fixed in a 5% sodium thiosulfide (Merck)
solution. Slides were then counterstained with light green
(Merck) dehydrated, cleared and mounted in synthetic
mounting medium (Entellan, Merck). Preparations were
then examined on a light microscope, using a 100× objec-
tive, and the mean AgNOR count per nucleus was deter-
mined in 100 neoplastic mast cells, as previously
described [35]. AgNORs were counted excluding areas of
necrosis and inflammation.
Immunohistochemistry
Monoclonal antibodies against Ki67 (MIB-1, Dakopatts,
Denmark) and polyclonal antibodies against CD117
(DakoCytomation, USA) were employed, using the avi-
din-biotin-peroxidase (ABC) method. Heat-induced anti-
gen retrieval (HIER) was performed: for Ki67, slides were
incubated for 30 minutes in a commercial antigen
retrieval solution (Dako), at 100°C in a water bath. For
CD117, slides were incubated in a 10 mM citrate buffer
(pH = 6.0) in a steamer, for 2 minutes. Endogenous per-
oxidase activity was blocked by immersing slides in meth-
anol containing 3% hydrogen peroxide for 10 minutes.
Anti-Ki67 and anti-CD117 antibodies were diluted at 1:50
and 1:450 in 5% bovine serum albumin, respectively.
Slides were incubated with antibodies overnight at 4°C.
Human gastrointestinal stromal tumours (GISTs) were
used as positive controls for CD117 staining. Detection
was performed using 3,3'-diaminobenzidine substrate
(Dako). Sections were then counterstained with Mayer's
haematoxylin, dehydrated, cleared and mounted in Entel-
lan mounting medium (Merck). Slides were evaluated
under light microscopy. The KI67 index was determined
in areas with high labelling immunoreactivity, excluding
areas of necrosis and inflammation, per 1000 cells, as pre-
viously described [36]. For CD117, three staining patterns
were recognized: a membrane-associated pattern with lit-
tle to none cytoplasmic staining, a focal (paranuclear or
Golgi-like) cytoplasmic pattern, with only occasional
minor membrane staining and a diffuse cytoplasmic pat-
tern [12-15].
Statistical analysis
Nonparametric analysis was conducted, using SPSS 14.0,
with a significance level of 5% and bilateral tests. Pear-
son's independent chi-squared test was used to assess the
correlations between CD117 immunostaining patterns
and several clinical and pathological variables. Kruskal-
Wallis test was used to assess differences between Ki67
median values and AgNORs mean counts of different var-
iables. A Spearman's correlation was calculated between
Ki67 labelling index and AgNORs mean counts.
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